Temat: "Chemotherapy, Adjuvant" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective.
Autorzy:: Bradbury M; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Savard MF; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Vandermeer L; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Clemons L; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Pond G; Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.
Hilton J; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Clemons M; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
McGee S; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Dec 14; Vol. 30 (12), pp. 10477-10487. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Chemotherapy, Adjuvant*/methods
Female ; Humans ; Canada ; Physicians ; Receptor, ErbB-2 ; Trastuzumab/therapeutic use

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Tumor response to neoadjuvant chemotherapy in molecular breast cancer subtypes in Medellin, Colombia. Retrospective cohort study
Autorzy:: Restrepo-Mejía M; Corporación Universitaria Remington, Medellín (Colombia).. .
Guarín-García AM; Corporación Universitaria Remington, Medellín (Colombia).. .
Bonilla-Sepúlveda ÓA; Corporación Universitaria Remington, Medellín (Colombia).. .
Rincón-Medina M; Corporación Universitaria Remington, Medellín (Colombia).. .
Barrera-Arenas LM; Corporación Universitaria Remington, Medellín (Colombia).. .
Transliterated Title:: Respuesta tumoral a la quimioterapia neoadyuvante en subtipos moleculares de cáncer de mama en Medellín, Colombia. Estudio de cohorte retrospectivo
Źródło:: Revista colombiana de obstetricia y ginecologia [Rev Colomb Obstet Ginecol] 2023 Jun 30; Vol. 74 (2), pp. 143-152. Date of Electronic Publication: 2023 Jun 30.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Chemotherapy, Adjuvant*
Neoadjuvant Therapy*
Adolescent ; Adult ; Female ; Humans ; Middle Aged ; Colombia/epidemiology ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.
Autorzy:: Wang X; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Lu C; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Wei B; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Li S; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Li Z; Department of Gastrointestinal Surgery, Peking University Cancer Hospital, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China.
Xue Y; Department of Gastroenterological Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang Province, 150081, China.
Ye Y; Department of Gastroenterological Surgery, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Zhang Z; Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, No.95 Yongan Road, Xicheng District, Beijing, 100050, China.
Sun Y; Department of General Surgery, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Liang H; Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China.
Li K; Department of Surgical Oncology, The First Hospital of China Medical University, No.155 Nanjing Street North, Heping District, Shenyang, Liaoning Province, 110002, China.
Zhu L; Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No.3 East Qingchun Road, Shangcheng District, Hangzhou, Zhejiang Province, 310016, China.
Zheng Z; Department of Gastric Surgery, Liaoning Cancer Hospital and Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, China.
Zhou Y; Department of General Surgery, The Affiliated Hospital of Qingdao University, No.16 Jiangsu Road, Shinan District, Qingdao, Shandong Province, 266000, China.
He Y; Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, No.58 Zhongshaner Road, Guangzhou, Guangdong Province, 510080, China.
Li F; Department of General Surgery, Xuanwu Hospital, Capital Medical University, No.45 Changchun Street, Xicheng District, Beijing, 100053, China.
Wang X; Department of General Surgery, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Liang P; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Dalian Medical University, No.222 Zhongshan Road, Xigang District, Dalian, Liaoning Province, 116011, China.
Huang H; Department of Gastric Surgery, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai, 200032, China.
Li G; Institute of General Surgery, General Hospital of Eastern Theater Command of Chinese PLA, No.305 East Zhongshan Road, Xuanwu District, Nanjing, Jiangsu Province, 210002, China.
Shen X; Division of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, No.109 West Xueyuan Road, Wenzhou, Zhejiang Province, 325027, China.
Ji J; Department of Gastrointestinal Surgery, Peking University Cancer Hospital, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China.
Tang Y; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Xu Z; Department of General Surgery, Jiangsu Province Hospital, No.300 Guangzhou Road, Gulou District, Nanjing, Jiangsu Province, 210029, China.
Chen L; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. .; Department of Gastrointestinal Surgery, Peking University International Hospital, No.1 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China. .
Corporate Authors:: RESONANCE study group
Źródło:: Journal of hematology & oncology [J Hematol Oncol] 2024 Apr 08; Vol. 17 (1), pp. 17. Date of Electronic Publication: 2024 Apr 08.
Typ publikacji:: Randomized Controlled Trial; Clinical Trial, Phase III; Letter
MeSH Terms:: Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/surgery
Humans ; Oxaliplatin/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Neoadjuvant Therapy

Raport

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Outcomes of neoadjuvant chemotherapy and radical hysterectomy for locally advanced cervical cancer at Kigali University Teaching Hospital, Rwanda: a retrospective descriptive study.
Autorzy:: Ngabonziza E; University of Rwanda, Kigali, Rwanda.
Ghebre R; University of Rwanda, Kigali, Rwanda.; University of Minnesota Medical School, Minneapolis, MN, USA.
DeBoer RJ; University of California, San Francisco, CA, USA.
Ntasumbumuyange D; University of Rwanda, Kigali, Rwanda.
Magriples U; University of Rwanda, Kigali, Rwanda.; Yale School of Medicine, New Haven, CT, USA.
George J; University of California, Irvine, CA, USA.
Grover S; University of Pennsylvania, Philadelphia, PA, USA.
Bazzett-Matabele L; University of Rwanda, Kigali, Rwanda. .; Yale School of Medicine, New Haven, CT, USA. .; Department of OBGYN, University of Botswana, Sir Ketumile Masire Teaching Hospital, Pvt Bag, 00713, Gaborone, Botswana. .
Źródło:: BMC women's health [BMC Womens Health] 2024 Mar 30; Vol. 24 (1), pp. 204. Date of Electronic Publication: 2024 Mar 30.
Typ publikacji:: Journal Article
MeSH Terms:: Uterine Cervical Neoplasms*/pathology
Carcinoma, Squamous Cell*/pathology
Humans ; Female ; Middle Aged ; Neoadjuvant Therapy ; Retrospective Studies ; Rwanda ; Universities ; Hospitals, Teaching ; Neoplasm Staging ; Hysterectomy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial.
Autorzy:: Lee KH; Department of Colorectal Surgery, Chungnam National University Hospital & College of Medicine, Daejeon, Korea.
Yang IJ; Department of Colorectal Surgery, Chungnam National University Hospital & College of Medicine, Daejeon, Korea.
Ha GW; Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Korea.
Lee J; Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.
Park YY; Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Lee SH; Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Lee JM; Department of Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
Bae JH; Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Park EJ; Division of Colorectal Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kim H; Department of Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim KY; Department of General Surgery, Wonkwang University Hospital & School of Medicine, Iksan, Korea.
An S; Department of Surgery, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Kim IY; Department of Surgery, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Kim JY; Department of Colorectal Surgery, Chungnam National University Hospital & College of Medicine, Daejeon, Korea. .
Źródło:: BMC cancer [BMC Cancer] 2024 Mar 29; Vol. 24 (1), pp. 397. Date of Electronic Publication: 2024 Mar 29.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Colonic Neoplasms*/pathology
Humans ; Young Adult ; Adult ; Middle Aged ; Aged ; Disease-Free Survival ; Chemotherapy, Adjuvant ; Progression-Free Survival ; Fluorouracil/adverse effects ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic ; Clinical Trials, Phase II as Topic

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.
Autorzy:: Pu H; Department of Oncology, Dazhou Central Hospital, Dazhou, 635000, Sichuan, China.
Yang W; Department of Oncology, Dazhou Central Hospital, Dazhou, 635000, Sichuan, China.
Liu M; School of Public Health, Kunming Medical University, Kunming, 650000, China.
Pang X; Department of Radiotherapy, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510655, China.
Chen Y; Department of Nursing, Dazhou Vocational and Technical College, Dazhou, 635000, Sichuan, China.
Xiong Q; Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, 650118, China. .; Yunnan Key Laboratory of Laboratory Medicine, Kunming, 650032, China. .; Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, 650032, China. .
Źródło:: Scientific reports [Sci Rep] 2024 Mar 22; Vol. 14 (1), pp. 6889. Date of Electronic Publication: 2024 Mar 22.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Carcinoembryonic Antigen*/analysis
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/surgery
Colonic Neoplasms*/pathology
Male ; Humans ; Middle Aged ; Aged ; Aged, 80 and over ; Retrospective Studies ; Prognosis ; China ; Chemotherapy, Adjuvant ; Neoplasm Staging

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients.
Autorzy:: Kim EY; Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Lee KH; Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Yun JS; Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Park YL; Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Park CH; Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jang SY; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Ryu JM; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Lee SK; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Chae BJ; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Lee JE; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Kim SW; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Nam SJ; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Yu JH; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea. .
Źródło:: BMC women's health [BMC Womens Health] 2024 Mar 20; Vol. 24 (1), pp. 187. Date of Electronic Publication: 2024 Mar 20.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Calcinosis*/diagnostic imaging
Calcinosis*/drug therapy
Calcinosis*/etiology
Humans ; Female ; Neoadjuvant Therapy/adverse effects ; Prognosis ; Breast/pathology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Retrospective Studies

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.
Autorzy:: Liu D; Department of Lamphoma and Abdominal Radiotherapy, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China.
Quan H; Department of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China.
Ma M; Department of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, 410013, Changsha, China.
Zhou H; Department of Gastroenterology and Urology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China.
Yang X; Department of Gastroenterology and Urology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China.
Wu Z; Department of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China.
Luo J; Department of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China.
Xiao H; Department of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, China. .; Department of Gastroduodenal and Pancreatic Surgery, Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, 410013, Changsha, China. .
Xiao Y; Department of Scientific Research, Changsha Health Vocational College, 410605, Changsha, China. .
Źródło:: BMC cancer [BMC Cancer] 2024 Mar 18; Vol. 24 (1), pp. 344. Date of Electronic Publication: 2024 Mar 18.
Typ publikacji:: Journal Article
MeSH Terms:: Nomograms*
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/surgery
Humans ; Retrospective Studies ; Prognosis ; Cohort Studies ; Chemotherapy, Adjuvant ; Gastrectomy

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Fulminant myocarditis during postoperative adjuvant chemotherapy for lung cancer with atezolizumab: a case report.
Autorzy:: Tokunaga T; Department of General Thoracic Surgery, Kagoshima City Hospital, 37-1, Uearatacho, Kagoshima, 890-8760, Japan. .; Department of General Thoracic Surgery, Kagoshima University Graduate School of Dental and Medical Science, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. .
Aoki M; Department of General Thoracic Surgery, Kagoshima University Graduate School of Dental and Medical Science, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.
Maruyama K; Department of General Thoracic Surgery, Kagoshima City Hospital, 37-1, Uearatacho, Kagoshima, 890-8760, Japan.
Nonaka Y; Department of General Thoracic Surgery, Kagoshima City Hospital, 37-1, Uearatacho, Kagoshima, 890-8760, Japan.
Kariatsumari K; Department of General Thoracic Surgery, Kagoshima City Hospital, 37-1, Uearatacho, Kagoshima, 890-8760, Japan.
Sakasegawa K; Department of General Thoracic Surgery, Kagoshima City Hospital, 37-1, Uearatacho, Kagoshima, 890-8760, Japan.
Ueda K; Department of General Thoracic Surgery, Kagoshima University Graduate School of Dental and Medical Science, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.
Źródło:: Journal of medical case reports [J Med Case Rep] 2024 Mar 16; Vol. 18 (1), pp. 162. Date of Electronic Publication: 2024 Mar 16.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Lung Neoplasms*/drug therapy
Lung Neoplasms*/complications
Myocarditis*/chemically induced
Female ; Humans ; Middle Aged ; Adjuvants, Immunologic/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Chemotherapy, Adjuvant/adverse effects

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol.
Autorzy:: Northgraves M; Hull Health Trials Unit, University of Hull, Hull, United Kingdom.
Cohen J; Hull Health Trials Unit, University of Hull, Hull, United Kingdom.
Harvey J; Nightingale Breast Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Huang C; Hull Health Trials Unit, University of Hull, Hull, United Kingdom.; Institute for Clinical and Applied Health Research (ICAHR), University of Hull, Hull, United Kingdom.
Palmieri C; Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom.
Pinder S; School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.; Department of Cellular Pathology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom.
Roy P; Department of Breast Surgery, Oxford University Hospitals NHS Foundation Trust, Oxfordshire, United Kingdom.
Reynia S; Exact Sciences UK, London, United Kingdom.
Soares M; Centre for Health Economics, University of York, York, United Kingdom.
Cain H; Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Źródło:: PloS one [PLoS One] 2024 Mar 15; Vol. 19 (3), pp. e0300339. Date of Electronic Publication: 2024 Mar 15 (Print Publication: 2024).
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Breast Neoplasms*/diagnosis
Breast Neoplasms*/genetics
Breast Neoplasms*/surgery
Carcinoma*/drug therapy
Humans ; Female ; Receptors, Estrogen/metabolism ; Chemotherapy, Adjuvant/methods ; Neoadjuvant Therapy ; Adjuvants, Immunologic/therapeutic use ; Gene Expression Profiling/methods ; Neoplasm Recurrence, Local/pathology ; Randomized Controlled Trials as Topic

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Autorzy:: Nguyen AQ; Department of Health Policy and Economics, Hanoi University of Public Health, Hanoi, Vietnam.
Tran OTM; Vietnam Strategy and Planning Institute, Hanoi, Vietnam.
Nguyen PK; Vietnam Strategy and Planning Institute, Hanoi, Vietnam.
Nguyen HT; Department of Health Policy and Economics, Hanoi University of Public Health, Hanoi, Vietnam.
Źródło:: PloS one [PLoS One] 2024 Mar 15; Vol. 19 (3), pp. e0300474. Date of Electronic Publication: 2024 Mar 15 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Biosimilar Pharmaceuticals*/therapeutic use
Humans ; Female ; Trastuzumab/therapeutic use ; Cost-Benefit Analysis ; Vietnam ; Receptor, ErbB-2 ; Antibodies, Monoclonal, Humanized/therapeutic use ; Chemotherapy, Adjuvant ; Quality-Adjusted Life Years

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution.
Autorzy:: Chinnadurai A; Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Breadner D; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. .
Baloush Z; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
Lohmann AE; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
Black M; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
D'Souza D; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Welch S; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Źródło:: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Mar; Vol. 35 (2), pp. e16. Date of Electronic Publication: 2023 Oct 16.
Typ publikacji:: Journal Article
MeSH Terms:: Paclitaxel*
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/radiotherapy
Adult ; Humans ; Female ; Middle Aged ; Aged ; Aged, 80 and over ; Carboplatin ; Follow-Up Studies ; Cohort Studies ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Staging ; Chemotherapy, Adjuvant/methods ; Radiotherapy, Adjuvant

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Study of neoadjuvant chemotherapy in advanced malignant ovarian germ cell tumors at a tertiary center in western India.
Autorzy:: Vasanth A; Department of Gynaecological Oncology, The Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Ahmedabad, India.
Patel SM; Department of Gynaecological Oncology, The Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Ahmedabad, India. .
Arora R; Department of Gynaecological Oncology, The Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Ahmedabad, India.
Parekh CD; Department of Gynaecological Oncology, The Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Ahmedabad, India.
Dave P; Department of Gynaecological Oncology, The Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Ahmedabad, India.
Patel BM; Department of Gynaecological Oncology, The Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Ahmedabad, India.
Vemanamandhi P; Department of Gynaecological Oncology, The Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Ahmedabad, India.
Źródło:: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Mar; Vol. 35 (2), pp. e19. Date of Electronic Publication: 2023 Oct 23.
Typ publikacji:: Journal Article
MeSH Terms:: Dysgerminoma*/drug therapy
Dysgerminoma*/etiology
Dysgerminoma*/pathology
Ovarian Neoplasms*/pathology
Neoplasms, Germ Cell and Embryonal*/drug therapy
Neoplasms, Germ Cell and Embryonal*/etiology
Neoplasms, Germ Cell and Embryonal*/pathology
Pregnancy ; Female ; Humans ; Young Adult ; Adult ; Neoadjuvant Therapy ; Retrospective Studies ; Chemotherapy, Adjuvant/adverse effects ; Neoplasm Staging
SCR Disease Name:: Ovarian Germ Cell Cancer

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Real-life experiences and barriers to adjuvant chemotherapy in Saudi patients with advanced stage II and stage III colon cancer.
Autorzy:: Alyabsi MS; Population Health Research Section, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Alqarni AH; Population Health Research Section, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Princess Noura Bint Abdul Rahman University, Health, and Rehabilitation Sciences College, Riyadh, Saudi Arabia.
Almutairi AF; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Alselaim NA; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Algarni MA; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Oncology, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.
Alshammari KM; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Oncology, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.
Źródło:: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2024 Mar 01; Vol. 30 (2), pp. 114-122. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:: Journal Article
MeSH Terms:: Fluorouracil*
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/epidemiology
Colonic Neoplasms*/pathology
Male ; Female ; Humans ; Oxaliplatin/therapeutic use ; Saudi Arabia/epidemiology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Patient-reported outcomes and symptom clusters pattern of chemotherapy-induced toxicity in patients with early breast cancer.
Autorzy:: Wiranata JA; Clinical Epidemiology Study Program, Master of Clinical Medicine Postgraduate Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.; Academic Hospital, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Hutajulu SH; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Astari YK; Research Scholar, Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Leo B; Specialty Program in Internal Medicine, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Bintoro BS; Department of Health Behaviour, Environment, and Social Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.; Center of Health Behaviour and Promotion, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Hardianti MS; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Taroeno-Hariadi KW; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Kurnianda J; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Purwanto I; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Źródło:: PloS one [PLoS One] 2024 Feb 23; Vol. 19 (2), pp. e0298928. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Humans ; Middle Aged ; Female ; Syndrome ; Antibiotics, Antineoplastic/therapeutic use ; Chemotherapy, Adjuvant/adverse effects ; Pain/drug therapy ; Patient Reported Outcome Measures

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
Autorzy:: Maione P; Division of Medical Oncology, S.G. Moscati Hospital, 83100 Avellino, Italy.
Salvi R; Division of Thoracic Surgery, S.G. Moscati Hospital, 83100 Avellino, Italy.
Gridelli C; Division of Medical Oncology, S.G. Moscati Hospital, 83100 Avellino, Italy.
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Feb 13; Vol. 31 (2), pp. 987-997. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Acrylamides*
Aniline Compounds*
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/surgery
Indoles*
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/surgery
Pyrimidines*
Humans ; Chemotherapy, Adjuvant ; ErbB Receptors/genetics ; Neoplasm Recurrence, Local/drug therapy

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
Autorzy:: Liao L; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Tang J; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Hong Z; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jiang W; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li Y; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Kong L; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Han K; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Hou Z; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhang C; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhou C; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhang L; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Sui Q; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xiao B; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Mei W; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yu J; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yang W; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Pan Z; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. .; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. .
Ding PR; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. .; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. .
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 02; Vol. 24 (1), pp. 164. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:: Journal Article
MeSH Terms:: DNA Mismatch Repair*
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/genetics
Colonic Neoplasms*/surgery
Brain Neoplasms*
Neoplastic Syndromes, Hereditary*
Colorectal Neoplasms*
Humans ; Retrospective Studies ; Oxaliplatin/therapeutic use ; Neoplasm Staging ; Carcinoembryonic Antigen ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Prognosis ; Chemotherapy, Adjuvant
SCR Disease Name:: Turcot syndrome

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
Autorzy:: Li Y; Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Zhao J; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Zhao Y; Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Li R; Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shan Dong, China.
Dong X; Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yao X; Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shan Dong, China.
Xia Z; Department of Oncology, Zibo Central Hospital, Binzhou Medical university, Zibo, Shandong, China.
Xu Y; Department of Pathology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China.
Li Y; Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Źródło:: Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e7030.
Typ publikacji:: Journal Article
MeSH Terms:: Lung Neoplasms*/drug therapy
Lung Neoplasms*/surgery
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/surgery
Adenocarcinoma of Lung*/pathology
Humans ; Retrospective Studies ; Neoplasm Staging ; Chemotherapy, Adjuvant

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
Autorzy:: Ju J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Gao SL; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute, Beijing, China.
Wang JY; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sang D; Department of Medical Oncology, Beijing Sanhuan Cancer Hospital, Beijing, China.
Kang YK; Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Wang X; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue J; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shuai Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qi YX; Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shi Jiazhuang, China.
Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Źródło:: Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (6), pp. 439-447. Date of Electronic Publication: 2024 Jan 07.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Breast Neoplasms*/pathology
Humans ; Adult ; Female ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Follow-Up Studies ; Prognosis ; Toremifene/therapeutic use ; Retrospective Studies ; Tamoxifen/therapeutic use ; Disease-Free Survival ; Chemotherapy, Adjuvant

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Transfer learning of pre-treatment quantitative ultrasound multi-parametric images for the prediction of breast cancer response to neoadjuvant chemotherapy.
Autorzy:: Falou O; Department of Physics, Toronto Metropolitan University, Toronto, ON, Canada. .; Institute for Biomedical Engineering, Science and Technology (iBEST), Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada. .
Sannachi L; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.; Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Haque M; Department of Physics, Toronto Metropolitan University, Toronto, ON, Canada.
Czarnota GJ; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.; Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Kolios MC; Department of Physics, Toronto Metropolitan University, Toronto, ON, Canada.; Institute for Biomedical Engineering, Science and Technology (iBEST), Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
Źródło:: Scientific reports [Sci Rep] 2024 Jan 29; Vol. 14 (1), pp. 2340. Date of Electronic Publication: 2024 Jan 29.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/diagnostic imaging
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Humans ; Female ; Neoadjuvant Therapy ; Ultrasonography/methods ; Chemotherapy, Adjuvant ; Machine Learning

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Chemotherapy, Adjuvant"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język